{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"units":"Participants"}],"description":"Will be defined as defined as a decrease of at least 25% in bone marrow blast counts or peripheral blood blast. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented.","groups":[{"description":"Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nDasatinib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Group I (Dasatinib)"},{"description":"Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSunitinib: Given PO\n\nSunitinib Malate: Given PO","id":"OG001","title":"Group II (Sutinib Malate)"},{"description":"Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nSorafenib: Given PO\n\nSorafenib Tosylate: Given PO","id":"OG002","title":"Group III (Sorafenib Tosylate)"},{"description":"Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPonatinib: Given PO\n\nPonatinib Hydrochloride: Given PO","id":"OG003","title":"Group IV (Ponatinib Hydrochloride)"},{"description":"Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPacritinib: Given PO\n\nPharmacological Study: Correlative studies","id":"OG004","title":"Group V (Pacritinib)"},{"description":"Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRuxolitinib: Given PO","id":"OG005","title":"Group VI (Ruxolitinib)"},{"description":"Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAntitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening\n\nIdelalisib: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies","id":"OG006","title":"Group VII (Idelalisib)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Zero patients enrolled in Ponatinib, Pacrtitinib, Ruxolitinib, and Idealisib arms.","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Clinical Activity","type":"PRIMARY","unitOfMeasure":"Participants"}